NASDAQ · NMTC
Healthcare · Medical - Devices
$1.56
Down-$0.06 (-3.85%)
Updated Sep 14, 2026, 11:30 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NMTC closed at $1.56 after 19 trading sessions, down 17.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.59 | $1.60 | $1.55 | $1.56 | 64.23K |
| Sep 10, 2026 | $1.65 | $1.67 | $1.56 | $1.58 | 225.22K |
| Sep 9, 2026 | $1.71 | $1.725 | $1.63 | $1.66 | 99.7K |
| Sep 8, 2026 | $1.68 | $1.73 | $1.58 | $1.69 | 275.01K |
| Sep 4, 2026 | $1.65 | $1.66 | $1.57 | $1.62 | 81.1K |
| Sep 3, 2026 | $1.68 | $1.73 | $1.6201 | $1.66 | 32.34K |
| Sep 2, 2026 | $1.60 | $1.80 | $1.5802 | $1.67 | 203.87K |
| Sep 1, 2026 | $1.67 | $1.72 | $1.60 | $1.61 | 72.18K |
| Aug 31, 2026 | $1.70 | $1.81 | $1.6161 | $1.70 | 259.33K |
| Aug 28, 2026 | $1.89 | $1.96 | $1.70 | $1.77 | 519.44K |
| Aug 27, 2026 | $2.16 | $3.49 | $1.89 | $1.98 | 13.92M |
| Aug 26, 2026 | $2.16 | $2.1656 | $2.00 | $2.00 | 10.4K |
| Aug 25, 2026 | $2.1602 | $2.20 | $2.10 | $2.16 | 24.19K |
| Aug 24, 2026 | $2.00 | $2.24 | $1.90 | $2.14 | 58.71K |
| Aug 21, 2026 | $2.15 | $2.1503 | $2.01 | $2.03 | 35.34K |
| Aug 20, 2026 | $2.18 | $2.3099 | $2.15 | $2.15 | 59.25K |
| Aug 19, 2026 | $1.88 | $2.37 | $1.865 | $2.18 | 85.86K |
| Aug 18, 2026 | $1.90 | $2.0899 | $1.82 | $1.88 | 47.31K |
| Aug 17, 2026 | $1.94 | $1.9756 | $1.85 | $1.88 | 30.47K |
The latest Smart Investors Daily articles mentioning NMTC.
NMTC research
Company profile and research snapshot.
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Maxim Group | Buy | — |
| May 13, 2026 | Ladenburg Thalmann | Buy | — |
| Mar 2, 2026 | Jones Trading | Buy | — |
| Sep 9, 2025 | Maxim Group | Buy | — |
| May 5, 2025 | Ladenburg Thalmann | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in
Benzinga · Aug 14, 2026
Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.
SeekingAlpha · Aug 13, 2026
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NMTC.
